Citryll’s Post

📣 Citryll is attending the 24th BioEquity Europe from the 12th to the 14th of May, in San Sebastián! Eduardo Bravo, CEO, and Tim Schenk, CBO, will be representing Citryll throughout the event and are looking forward to presenting our recent progress, exchanging insights and forging valuable partnerships with industry leaders and investors! If you are attending, be sure to reach out to us directly or through BioEquity’s partnering system to schedule a meeting and learn more about Citryll’s ground-breaking science on Neutrophil Extracellular Trap (NETs) and NETosis inhibition for the treatment of inflammatory diseases. ↪ You can learn more about the BioEquity Europe through the following link: https://lnkd.in/dzunkQc

🌟 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗮𝘁 𝗪𝗢𝗗𝗖 𝘁𝗼𝗱𝗮𝘆 𝗮𝘁 𝗯𝗼𝗼𝘁𝗵 𝟭𝟬𝟳! 🌟 Discover how Inbeeo can help your company navigate market access challenges in rare diseases across Europe. Let’s discuss tailored 𝗟𝘂𝗻𝗰𝗵 & 𝗟𝗲𝗮𝗿𝗻 sessions designed specifically for your organization’s needs! 🍽️✨These insightful sessions are a simple and effective way to refine your value strategy and optimize pricing approaches. If you're attending, swing by booth 107! 📍 Erin Haney and Christel Jansen are eager to explore how we can support your journey in the orphan drug space. Let’s transform your challenges into opportunities together! 💡✨🚀 #wodc #innovation #raredisease #marketaccess #orphandrugs #Lunchandlearn

#AMR is an important issue - if you want an update on progress being made on addressing the ‘AMR silent pandemic’ do register for this free webinar. Looking forward to chairing the webinar, insightful updates from the expert panel and an engaging Q&A.

Nice cover indeed! And more to discover on host immunity & microbiota interplay!

Today marks the final day of the World Orphan Drug Congress Europe 2024 in Barcelona. It's a pleasure to connect with new colleagues who are making a significant impact in the rare diseases field, especially those working with children. Your work is invaluable, and we are here to support you in navigating the challenges and exploring opportunities and regulations in this field. The consensus is clear: we are committed to working in partnership across Europe and the world to ensure inclusivity and, most importantly, patient centricity in all our approaches. This shared commitment is the cornerstone of our collective effort and will continue to drive our work in the rare diseases field. #rarediseases #drugdiscovery #mitochondrial #StemnovateLimited #WorldOrphanDrugCongressEurope #Veristat #AnaManchón

In 2018, bioMérieux offered me the incredible opportunity to join the Global Health department and lead the Fleming Fund project. This marked the beginning of a personal commitment to deeply understand the complexities of antimicrobial resistance (AMR), the challenges faced by emerging countries, and how to better position bioMérieux's solutions to support the success of the Fleming Fund, with the unwavering support of our outstanding regional teams. Now, six years later, I look back with gratitude for the chance to collaborate with remarkable individuals across all the countries where the Fleming Fund entrusted us in Africa, in South Asia and in India and neighboring countries. I am particularly thankful for the shared dedication with local teams in the fight against AMR, and the tremendous collective efforts to make a meaningful impact. Among the many inspiring people I’ve encountered, two have been key in guiding our approach and strengthening our resolve to improve antibiotic usage, enhance microbiology expertise, and support clinicians in delivering better patient care. Last week, during multiple meetings held at the United Nations General Assembly in New York, a true zenith in global health discussions, I had the honor of meeting Dame Sally Davies for the first time and reconnecting with Tom Pilcher, with whom I’ve had the privilege of collaborating on numerous occasions. I am deeply grateful to bioMérieux for this journey and the opportunity to contribute to a cause that is critical to global health. However, the story is far from over—our fight against antimicrobial resistance continues. Together, we must carry forward the efforts we’ve made in these early years and remain steadfast in our mission to protect global health. #GlobalHealth #AntimicrobialResistance #AMR #AntibioticUsage #FlemingFund #bioMérieux #HealthcareInnovation #UNGA #UnitedNations #EmergingMarkets #PatientCare #Microbiology #AntibioticStewardship #FightAMR #PublicHealth #DameSallyDavies #TomPilcher

📅 Rare Diseases Forum 2024: securing Europe's competitiveness in research and development for people living with rare diseases. Register now to join Global Counsel on Tuesday, April 16 for a wide-ranging discussion convening policy makers, industry, patient organisations and academia for a series of panel discussions and keynotes focused on the EU's role in enhancing competitiveness in life sciences, fostering investment in the rare-diseases sector and examining the benefits of a competitive agenda for those living with rare diseases. Find out more about our speakers and programme, and register, at https://lnkd.in/dxufY4hJ. We are convening the Rare Diseases Forum on behalf of our event partners EURORDIS-Rare Diseases Europe, RARE DISEASES ORGANISATION BELGIUM, EFPIA - European Federation of Pharmaceutical Industries and Associations, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, EuropaBio - the European Association for Bioindustries, pharma.be, UCB, Novo Nordisk, Sanofi and Takeda.

Join us tomorrow to learn how to use patient-generated data in medical device development!

Are you at the 14th Congress on Autoimmunity in Ljubljana? Visit us at booth 12, and don't miss our presentation on Diagnostics in Autoimmunity, with Dr Makoto Miyara (France), today at 12:50. Read the abstract: 🔗 https://bit.ly/3USVQvw #Autoimmunity2024

Thanks to Dr. Miyara for sharing your insights and how we can better partner with you to enable faster patient diagnosis and link to care.